The name game

Abstract

Pre-licensing demand for biopharmaceuticals is growing. Advance publicity about biological medicines, many of them addressing life-threatening diseases such as cancer and AIDS, is ensuring that doctors, pharmacists and, not least, patients, are increasingly aware of products in development and, unsurprisingly, want early access to them.